OncoKB New Data Release - February 27, 2026

[Contact OncoKB]

Data Release v6.2 

February 27, 2026

What's New

• Update to our FDA-Approved Oncology Therapies page

• Updates to the functional classification of the following genes:

Gene	Previous Gene Classification	New Gene Classification
KLHL6	Oncogene, Tumor Suppressor	Tumor Suppressor
MEF2C	Oncogene, Tumor Suppressor	Oncogene
MITF	Oncogene, Tumor Suppressor	Oncogene
NSD1	Oncogene, Tumor Suppressor	Tumor Suppressor
PRKCB	Oncogene, Tumor Suppressor	Oncogene
PTPN1	Oncogene, Tumor Suppressor	Tumor Suppressor
SERPINB3	Oncogene, Tumor Suppressor	Insufficient evidence to classify as an Oncogene or Tumor Suppressor
SMARCE1	Oncogene, Tumor Suppressor	Insufficient evidence to classify as an Oncogene or Tumor Suppressor
SOX9	Oncogene, Tumor Suppressor	Tumor Suppressor
ZBTB20	Oncogene, Tumor Suppressor	Oncogene

Updated Therapeutic Implications:

• Removal of therapy(s) associated with a tumor type-specific leveled alteration(s) (without changing the alteration's highest level of evidence) 

• Level R2: Removal of Panitumumab from EGFR S492R in colorectal cancer as data does not support EGFR S492R conferring resistance to panitumumab in colorectal cancer (PMID: 22270724, 26059438)

• Level R2 resistance-associated therapeutics currently in OncoKB™ for EGFR S492R in colorectal cancer: Cetuximab

Gene Curation:

• Addition of 13 new genes:

ACACA ACP3 ACSL4 CARS1 CHUK D2HGDH HOXA13 MDH2 MASTL NFKBIE TNFRSF9 TOX XRCC3

We're Here to Help

As always, don’t hesitate to reach out if you have comments, questions or suggestions. We love to hear from you. You can reach us at con...@oncokb.org

www.oncokb.org

--

The OncoKB Team